WO2017196210A1 - Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2h-пиридо[3,2-b][1,4]оксазин-3(4h)-она для медицинского применения - Google Patents
Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2h-пиридо[3,2-b][1,4]оксазин-3(4h)-она для медицинского применения Download PDFInfo
- Publication number
- WO2017196210A1 WO2017196210A1 PCT/RU2017/050037 RU2017050037W WO2017196210A1 WO 2017196210 A1 WO2017196210 A1 WO 2017196210A1 RU 2017050037 W RU2017050037 W RU 2017050037W WO 2017196210 A1 WO2017196210 A1 WO 2017196210A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kinase
- salt
- compound
- amino
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- This invention relates to the chemistry of organic compounds, pharmacology and medicine, namely to the salt form of the compound, as well as its crystalline (polymorphic) forms, which are promising for the treatment of diseases of the musculoskeletal system associated with impaired metabolism of bone and / or cartilage in particular osteoporosis, osteoarthrosis and osteochondrosis.
- Osteoporosis is the most common bone disease in humans. This is a chronic systemic disease of bone tissue, which is characterized by a decrease in bone mass and the development of violations of the bone microarchitecture, which leads to a decrease in bone strength and a predisposition to pathological fractures.
- Currently, two main types of osteoporosis are distinguished - primary and secondary.
- drugs for the treatment of osteoporosis drugs that slow bone resorption (estrogens, selective modulators of estrogen receptors, tissue-selective regulators of estrogenic activity, calcitones, bisphosphonates and other drugs (odanakatib, denosumab and others) are used); drugs that stimulate bone formation (fluorides, growth hormone, anabolic steroids, androgens); multidimensional drugs (strontium ranelate, active metabolites of vitamin D, ossein-hydroxyapatite complex).
- Osteoarthrosis is considered as an organ lesion, i.e. a disease of the entire joint, in which all components of the joint are involved in the pathological process: cartilage, subchondral bone, synovial membrane, ligaments, capsule, muscles. So far, OA treatment is primarily aimed at the symptoms of the disease, i.e. to reduce pain, improve the functional state of the joints and slow the development of pathology. Symptomatic effects are achieved by a combination of non-pharmacological and drug methods described in numerous recommendations. Existing methods of treatment in most cases do not allow to achieve restoration of joint tissues, prevent the development of pathology, or at least a long and reliable restriction of disease progression.
- Protein kinases are an important family of proteins involved in the regulation of key cellular processes, the violation of the activity of which can lead to various diseases.
- a promising approach for the treatment of diseases associated with impaired activity of protein kinases is the use of low molecular weight chemical compounds to inhibit their activity.
- Examples of such inhibitors approved for use in clinical practice are: Imatinib (Imatinib), Nilotinib (Nilotinib), Dasatinitib (Dasatinib), Sunitinib (Soitenib), Sorafenib (Sorafenib), Lapatinib (Lapatinib), Gefitinib ( Erlotinib), Crizotinib (Crizotinib).
- Imatinib Imatinib
- Nilotinib Nilotinib
- Dasatinitib Dasatinitib
- Sunitinib Soitenib
- Sorafenib Sorafen
- c-Src kinase Proton-oncogene tyrosine-protein kinase is a tyrosine kinase that is not associated with the cellular receptor and is involved in embryonic development and cell growth. In various in vitro models, inhibition of c-Src kinase has been shown to block actin ring formation and prevent osteoclast-mediated bone destruction. In addition, c-Src kinase is involved in signaling cascades leading to hypertrophic changes in chondrocytes associated with aberrant cartilage metabolism characteristic of diseases associated with degenerative-degenerative processes of this tissue.
- Saracatinib has previously been shown to be a new competitive inhibitor of Src kinase, which inhibits bone resorption in vitro. During phase I clinical trials, it was found that Saracatinib inhibits osteoclast-mediated bone resorption in healthy men without any side effects (RA Hannon, G. Clack, M. Rimmer et al. Effects of the Src kinase inhibitor saracatinib ( AZD0530) on bone turnover in healthy men: a randomized, doubleblind, placebo- controlled, multiple ascending dose phase I trial.// J Bone Miner Res. 2010. V. 25. N ° 3. P. 463-71.). However, as further clinical studies have shown, the high toxicity of Saracatinib with daily use in a therapeutically effective dose makes it impossible to use this drug in clinical practice for the treatment of diseases of the musculoskeletal system.
- the present invention is to develop a new drug effective for the treatment of diseases of the musculoskeletal system, in particular, osteoarthritis, osteoporosis, and with acceptable pharmacokinetic parameters.
- the technical result of this invention is the development and preparation of an effective kinase inhibitor, in particular c-Src kinase, characterized by high inhibitory activity and pharmacokinetic characteristics, in particular, a high maximum and average daily concentration, as well as a high value of the parameter AUC ⁇ (area under the curve "concentration - time ”) in the blood of animals and humans, allowing the use of this inhibitor for the treatment of diseases associated with aberrant kinase activity, leading to impaired m metabolic bone and cartilage, in particular for diseases of the musculoskeletal system, in particular, osteoarthritis, osteoporosis.
- a kinase inhibitor in particular c-Src kinase, characterized by ease of scaling of the preparation and purification process, as well as by high purity of the obtained product with minimal use of purification steps of the obtained compound.
- the salt of 4-methylbenzenesulfonic acid and a 2,2-dimethyl-6 - base is ((4 - ((3,4,5-trimethoxyphenyl) amino) -1, 3,5-triazin-2-yl) amino) -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one is a hydrate, as well as its polymorphic modifications.
- Some embodiments of the invention are 4-methylbenzenesulfonic acid monohydrate and 2,2-dimethyl-6 - (- 4 - ((3,4,5-trimethoxyphenyl) amino) -1, 3,5-triazin-2-yl) amino monohydrate -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one, as well as its polymorphic modifications.
- Space group P2 c The positions of the characteristic diffraction peaks on the Debye of this polymorphic modification (2 ⁇ ): 6.2; 8.8; 9.6; 10.7; 1 1, 0; 1 1, 6; 12.4; 15.3; 16.2; 16.5; 17.0; 17.4; 17.6; 17.9; 18.3; 18.6; 19.3; 19.3; 19.6; 20.6; 20.9; 23.5; 25.2; 26.2; 26.5; 27.2; 27.6; 30.2.
- the present invention also relates to the use of a salt or its hydrate, solvate, as well as the polymorphic modifications of the invention as an inhibitor of aberrant kinase activity.
- the kinase is a non-receptor protein kinase, in particular, the kinase is selected from the Syk kinase or kinase of the Src family.
- the kinase of the Src family is c-Src, Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck or Lck kinase.
- the kinase is a non-receptor protein kinase, in particular, the kinase is selected from the Syk kinase or kinase of the 8gs family.
- the kinase of the Src family is c-Src, Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck or Lck kinase.
- compositions for the prevention and / or treatment of a disorder associated with aberrant kinase activity contain an effective amount of the salt of the invention and at least one pharmaceutically acceptable excipient.
- the excipient is a pharmaceutically acceptable carrier and / or excipient.
- Such compositions are intended to modulate the activity of kinases representing a non-receptor protein kinase, in particular, the kinase selected from the Syk kinase or kinase of the Src family.
- the kinase of the Src family is c-Src, Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck or Lck kinase.
- the invention also includes a method of preventing and / or treating a disorder associated with aberrant kinase activity in the body, comprising administering to the specified organism a pharmaceutical composition of the invention.
- a disorder associated with aberrant kinase activity is a disease associated with a violation of the metabolism of bone and cartilage, in particular, diseases of the musculoskeletal system.
- the disease of the musculoskeletal system is osteoarthrosis or osteoporosis.
- the organism is a human or animal.
- the animal is a cat, dog, or horse.
- the method for producing crystals of the compounds of the invention comprising the following steps: but. introducing a solution of 4-methylbenzenesulfonic acid or its hydrate in an organic solvent into a suspension or solution of 2,2-dimethyl-6 - ((4- ((3,4,5-trimethoxyphenyl) amino) -1, 3,5-triazin-2- il) amino) -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one in an organic solvent or mixture of solvents; the introduction of a solution of 4-methylbenzenesulfonic acid or its hydrate can be carried out both at room temperature and by heating or cooling each of the components; the reverse order of mixing reagents can also be used;
- the solvent in step (a) used to prepare the solution of 4-methylbenzenesulfonic acid or its hydrate is ethanol.
- the salt is recrystallized after step (c).
- an additional stage is used to initiate the formation of crystals in cases of obtaining salt from solutions.
- the initiation of crystal formation can be achieved by adding 4-methylbenzenesulfonic acid salt and 2,2-dimethyl-6 - ((4 - ((3,4,5-trimethoxyphenyl) amino) -1, 3,5-triazine- 2-yl) amino) - 2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one or by any other known method.
- Compound 1 2,2-dimethyl-6 - ((4- ((3,4,5-trimethoxy-phenyl) amino) -1 5-triazin-2-yl) amino) -2H-pyrido [3,2-b] [1, 4] oxazine-3 (4H) -one (hereinafter referred to as Compound 1) has modulating activity against Src kinases, in particular, against a human c-Src kinase with a half-maximal inhibitory concentration of nanomolar range.
- this compound does not have acceptable pharmacokinetic characteristics that can be used in clinical practice as a medicine for the treatment of diseases associated with aberrant kinase activity leading to aberrant metabolism of bone and cartilage tissue. So, in particular, when studying the pharmacokinetics of Compound 1 when administered orally to rats at a dose of 30 mg / kg, the maximum concentration in the blood plasma of animals was 100 times lower than the minimum effective concentration determined in the efficacy studies (for more details, see the “Examples” section).
- Such diseases include, for example, osteoporosis, in particular secondary osteoporosis and especially secondary osteoporosis in rheumatoid arthritis.
- the salt of 4-methylbenzenesulfonic acid and Compound 1, as well as its hydrate (in particular monohydrate) and / or polymorphic modifications can be used to treat diseases associated with a decrease in mineral mass and bone density, a change in bone quality due to impaired microarchitectonics, accumulation microdamages, mineralization disorders and bone remodeling rate.
- 4-methylbenzenesulfonic acids and Compounds 1, as well as its solvate, hydrate (in particular, monohydrate) and polymorphic modifications, have suitable pharmacokinetic parameters and can be used for therapy diseases characterized by aberrant metabolism of bone and cartilage. It was unexpectedly found that the use of a salt of 4-methylbenzenesulfonic acid and Compound 1 with a single administration can be carried out in a significantly lower dose compared to other salt forms of Compound 1 to achieve the desired therapeutic effect.
- the hydrate of the salt of 4-methylbenzenesulfonic acid and Compound 1 has linear pharmacokinetics in a wide range of doses - with intragastric administration of the drug to Wistar rats.
- the average daily concentration of Compound 1 in target organs (bone and cartilage) is more than three times the average daily concentration of Compound 1 in animal blood plasma.
- an Src kinase inhibitor in particular, the c-Src kinase of the invention, as a drug for monotherapy or in combination with other therapies for diseases of the musculoskeletal system will allow achieving a significant and long-term remission.
- the c-Src kinase inhibitor according to the invention can be used as a maintenance therapy designed to prevent possible relapses in patients in need of such treatment.
- Figure 4 X-ray diffraction patterns of hydrochloric acid salt powder and Compound 1: a) sample S-3-10-B-HCI; b) sample S-3-1 1 -C2-HCI.
- Figure 13 1 H and 13 C nuclear magnetic resonance spectra of a sample of 4-methylbenzenesulfonic acid salt hydrate and Compound 1 (polymorphic modification “A”): a) 1 H-NMR spectrum (Bruker DRX500.13400, 500, 13 MHz, DMSO-iser ⁇ );
- Figure 14 1 H and 13 C nuclear magnetic resonance spectra of a sample of 4-methylbenzenesulfonic acid salt hydrate and Compound 1 (polymorphic modification “B”): a) 1 H-NMR spectrum (Bruker DRX500, 13, 500, 13 MHz, flMCO-d6 );
- Figure 18 Effect of Saracatinib, Bosutinib, and Compound 1 on the relative resorption of the mineralized matrix.
- Figure 19 Average plasma concentrations of Compound 1 in Wistar rats after a single oral administration of a free base at a dose of 30 mg / kg. For each time point, average values are determined based on individual data from three animals.
- Figure 20 Average concentrations of Compound 1 in the blood plasma of Wistar rats after a single oral administration of Compound 1 mesylate at a dose of 30 mg / kg (in terms of free base). For each time point, average values are determined based on individual data from three animals.
- Figure 21 Average concentrations of Compound 1 in the blood plasma of Wistar rats after a single oral administration of 4-methylbenzenesulfonic acid salt hydrate and Compound 1 (polymorphic modification “A”) at a dose of 21 mg / kg (in terms of free base). For each time point, average values are determined based on individual data from six animals.
- Compound 1 refers to 2,2-dimethyl-6 - ((4 - ((3,4,5-trimethoxy-phenyl) amino) -1, 3,5-triazine-2- il) amino) -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one, also represented by the structural formula:
- C when used with reference to temperature means a centigrade or Celsius temperature scale.
- IC 50 means the concentration of the test compound at which half-maximum inhibition of kinase activity is achieved.
- suspension refers to a solid suspended in a liquid medium, usually water or an organic solvent.
- modulation refers to a change in the catalytic activity of a kinase.
- modulation refers to the activation or inhibition of the catalytic activity of a kinase.
- polymorphic modification refers to the solid phase of a substance, which manifests itself in several different forms, due to the different arrangement and / or conformation of the molecules in the crystal lattice. Polymorphic modifications usually have different chemical and physical properties.
- polymorphic modification also refers to solvates, hydrates (ie, crystalline forms containing a solvent or water), as well as various unsolvated and non-hydrated crystalline forms of the compound.
- solvate is used to describe a molecular complex comprising a compound of the invention and one or more molecules of a pharmaceutically acceptable solvent, for example ethanol.
- hydrate is used when the specified solvent is water.
- X-ray powder diffraction pattern or “PXRD pattern” refers to the experimentally observed diffraction pattern or the parameters obtained from it. Usually, X-ray powder diffraction patterns are characterized by the position of the peak (along the abscissa) and the intensity of the peak (along the ordinate).
- peak intensity refers to the relative signal intensity in a given X-ray diffraction pattern. Factors affecting the relative peak intensity are sample thickness and preferred orientation (i.e., the distribution of crystalline particles is not random).
- peak position refers to the position of the x-ray reflex, measured and observed in experiments by powder diffraction.
- Peaks identified by their respective position are obtained from the diffraction pattern for various polymorphic forms of the salts of 2,2-dimethyl-6 - ((4 - ((3,4,5-trimethoxyphenyl) amino) -1 5-triazin-2 -yl) amino) -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) - she.
- 2 theta value refers to the position of the peak in degrees, based on the experimental X-ray diffraction data, and basically represents the unit of measurement on the abscissa axis in the diffraction patterns.
- ⁇ is the angle at which the diffraction condition is satisfied for a given wavelength.
- the angle between the direction of the diffraction beam and the primary beam is 2 ⁇ . It should be understood that reference in this application to specific 2 ⁇ values for a specific polymorphic form implies a 2 ⁇ value in degrees, measured using the experimental X-ray diffraction conditions disclosed in this application.
- aberrant activity of a kinase in this document means a kinase activity that is significantly different from the base level of activity of this kinase in cells in the absence of pathology. Aberrant activity can be caused by a change in the kinase expression level, disruption of the processes leading to kinase activation, deregulation of degradation pathways, and other factors.
- excipient means any pharmaceutically acceptable substance of inorganic or organic origin that is part of the drug or used in the manufacturing process, manufacture of the drug to give it the necessary physicochemical properties.
- AUC area under the curve
- AUC means a pharmacokinetic parameter characterizing the total concentration of a drug in a blood plasma during the entire observation period. Mathematically defined as an integral from 0 to
- 00 functions of the concentration of the drug (pharmacokinetic curve) in blood plasma versus time and is equal to the area of the figure bounded by the pharmacokinetic curve and coordinate axes.
- Src family kinase is a family of mammalian non-receptor tyrosine protein kinases that are similar in structure to c-Sre kinase. In vertebrates, nine kinases of the Src family are known: Src. Yes, Fgr, Fyn, Lyn, Hck, Lck, Blk, Frk. Kinases of this family are involved in the regulation of cell growth, intracellular signal transmission, and in particular, the signaling pathways of T and B cell receptors, adhesive cell interactions, etc.
- c-Src kinase plays a key role in the formation of the actin ring, a unique osteoclast cytoskeleton necessary for bone resorption.
- Syk kinase is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction by antigenic and Fc receptors, BCR, and other receptors. Syk kinase is most intensively expressed in hematopoietic cells (such as macrophages, mast cells, white blood cells, platelets and red blood cells), to a lesser extent - in epithelial cells, fibroblasts, neuronal cells, hepatocytes, etc. (Yanagi, S., et al., Biochem Biophys Res Commun, 2001, 288, 495-8).
- hematopoietic cells such as macrophages, mast cells, white blood cells, platelets and red blood cells
- Syk kinase is involved in the development of adaptive immunity and is important in the function of additional cell types, including platelets, phagocytes, fibroblasts, and osteoclasts. Syk kinase plays a role in the differentiation and functioning of osteoclasts. In addition, Syk kinase plays a role in osteolysis.
- treatment cover the treatment of pathological conditions in mammals, preferably in humans, and include: a) reduction, b) blocking (suspension) of the course of the disease, c) alleviation of the severity of the disease, i.e. inducing a regression of the disease; d) reversing the disease or condition to which the term is applied, or one or more symptoms of the disease or condition.
- prevention covers the elimination of risk factors, as well as the prophylactic treatment of subclinical stages of the disease in mammals, preferably in humans, aimed at reducing the likelihood of clinical stages of the disease.
- Patients for prophylactic therapy are selected based on factors that, based on known data, entail an increased risk of clinical stages of the disease compared with the general population.
- Preventive therapy includes a) primary prevention and b) secondary prevention.
- Primary prophylaxis is defined as prophylactic treatment in patients whose clinical stage of the disease has not yet begun. Secondary prophylaxis is the prevention of the repeated onset of the same or similar clinical condition of the disease.
- the compounds of the present invention are promising for the treatment of diseases of the musculoskeletal system associated with a violation of the metabolism of bone and / or cartilage tissue and degenerative degenerative processes in them, in particular, osteoporosis, osteoarthritis (deforming arthrosis) and osteochondrosis of any etiology having both systemic and and local nature, including those due to primary pathological changes in these tissues, or associated with various diseases or prolonged use of certain medications atov.
- the compounds of the invention can be used to treat postmenopausal osteoporosis, senile, drug osteoporosis, osteoporosis in malignant neoplasms, secondary osteoporosis in rheumatoid arthritis, gonarthrosis, coxarthrosis, lumbar, thoracic, cervical osteochondrosis, etc.
- Finding the right salt for the right drug is an important point in the preclinical phase of drug development.
- Changing the salt form of the active substance of the drug is a common means of modifying its chemical and biological characteristics, not leading to a modification of its structure.
- the choice of a particular salt form can deeply affect the physicochemical properties of a given drug (for example, dissolution rate, solubility, stability, and hygroscopicity).
- Replacing one salt form in a drug with another can change the therapeutic efficacy, safety of use and / or quality, which are especially important for the optimal composition of the dosage form of large-scale production.
- Solid salt forms are usually preferred for oral formulations, since they are the ones that tend to exhibit the desired physical characteristics; and in the case of essential drugs, acid addition salts are often the preferred salt form.
- different salt forms vary greatly in their ability to impart desired properties (such as storage stability, ease of preparation and purification process, pharmacokinetic parameters), and such properties cannot be predicted with sufficient accuracy.
- some salts are solids at ambient temperature, while other salts are liquids, viscous oils, or resins.
- some salt forms are stable to heat and light under extreme conditions, while others decompose easily under much milder conditions.
- the development of a suitable form of an acid addition salt of an essential drug for use in a pharmaceutical composition is an extremely important and far from always predictable process.
- Pharmacokinetic parameters are the most important characteristics that determine the suitability of a solid salt form (or a specific polymorphic modification) for use as a medicine.
- the average daily and maximum concentration of the drug in the blood of animals and humans can significantly depend on the composition of the salt form and its polymorphic modification.
- the possibility of large-scale production of the selected salt form of the drug substance and the purity (or difficulty of purification) of the resulting product are also extremely important characteristics that significantly depend on the selected salt form.
- suitable salt forms should not show significant changes in physicochemical characteristics (chemical composition, water content, density, hygroscopicity, solubility, etc.) during storage for a substantial period of time.
- Solids including pharmaceutically active compounds, often have more than one crystalline form, known as polymorphism.
- Polymorphism occurs when a compound crystallizes in many different solid phases, which differ in crystalline packing.
- polymorphic modifications have different physical characteristics, including solubility and physical and chemical stability.
- Different solid salt forms of the same drug substance, moreover, different polymorphs of the same solid salt form can differ in the rate of release of the drug, in the stability of the solid state of the salt form, and in suitability for the manufacture of a pharmaceutical preparation.
- the subject of the invention also includes the administration to a subject in need of appropriate treatment of a therapeutically effective amount of a compound of the invention.
- a therapeutically effective amount is meant an amount of a compound administered or delivered to a patient in which the patient is most likely to exhibit the desired response to treatment (prophylaxis).
- the exact amount required can vary from subject to subject, depending on the age, body weight and general condition of the patient, the severity of the disease, the method of administration of the drug, combined treatment with other drugs, etc.
- the compound of the invention or a pharmaceutical composition containing the compound can be administered to the patient in any quantity (preferably, the daily dose of the active substance is up to 1.5 g per patient per day, most preferably the daily dose is 200-500 mg / day) and any route of administration (preferably an oral route of administration) effective for treating or preventing a disease.
- the daily dose of the active substance is up to 1.5 g per patient per day, most preferably the daily dose is 200-500 mg / day
- any route of administration preferably an oral route of administration
- compositions comprising the essence of the invention can be administered orally, parenterally, topically, and the like to the human or other animals.
- the introduction can be carried out both once and several times a day, week (or any other time interval), or from time to time.
- the compound can be introduced into the patient’s body daily for a certain period of days (for example, 2-10 days), and then a period without taking the substance (for example, 1-30 days).
- a dose of each of the components of the combination therapy is administered during the required treatment period.
- the compounds that make up the combination therapy can be administered to the patient as a single dose, in the form of a dosage containing all the components, and in the form of individual dosages of the components.
- the invention also relates to pharmaceutical compositions that contain the compounds of the invention (or a prodrug or other pharmaceutically acceptable derivative) and one or more pharmaceutically acceptable carriers, adjuvants, solvents and / or excipients, such as can be administered to the patient along with the compound constituting the essence of the present invention, and which do not destroy the pharmacological activity of this compound, and are non-toxic when administered in doses sufficient to delivering a therapeutic amount of a compound.
- compositions of this invention comprise the compounds of this invention together with pharmaceutically acceptable carriers, which may include any solvents, diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, astringents, lubricants materials, etc., suitable for a particular dosage form.
- pharmaceutically acceptable carriers may include any solvents, diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, astringents, lubricants materials, etc.
- Materials that may serve as pharmaceutically acceptable carriers include, but are not limited to, mono- and oligosaccharides, as well as their derivatives; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut, cottonseed, safrole, sesame, olive, corn and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic solution, Ringer's solution; ethyl alcohol and phosphate buffers.
- excipients such as cocoa butter and suppository wax
- oils such as peanut, cottonseed, safrole, sesame, olive, corn and soybean oil
- glycols such as propylene glycol
- esters such as ethyl oleate and ethyl laur
- composition of the composition may be other non-toxic compatible lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as dyes, release fluids, film-forming agents, sweeteners, flavors and fragrances, preservatives and antioxidants.
- non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate
- dyes such as sodium lauryl sulfate and magnesium stearate
- release fluids such as sodium lauryl sulfate and magnesium stearate
- film-forming agents such as sodium lauryl sulfate and magnesium stearate
- sweeteners such as sodium lauryl sulfate and magnesium stearate
- flavors and fragrances such as sodium lauryl sulfate and magnesium stearate
- preservatives and antioxidants such as sodium lauryl sulfate and magnesium stearate
- the subject of this invention is also dosage forms — a class of pharmaceutical compositions whose composition is optimized for a particular route of administration into the body in a therapeutically effective dose, for example, for administration to the body orally, topically, pulmonally, for example, as an inhalation spray, or intravascularly, intranasally , subcutaneously, intramuscularly, as well as by the infusion method, in recommended dosages.
- Dosage forms of the present invention may contain formulations prepared using liposome methods, microencapsulation methods, methods for preparing nanoforms of the preparation, or other methods known in the pharmaceutical art.
- the active principle is mixed with one or more pharmaceutical excipients such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose or the like.
- pharmaceutical excipients such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose or the like.
- Tablets may be coated with sucrose, a cellulosic derivative, or other suitable coating materials. Tablets can be prepared in various ways, such as direct compression, dry or wet granulation, or hot fusion.
- a pharmaceutical composition in the form of a gelatin capsule can be prepared by mixing the active principle with a solvent and filling the mixture with soft or hard capsules.
- aqueous suspensions, isotonic saline solutions or sterile injectable solutions are used that contain pharmacologically compatible agents, for example propylene glycol or butylene glycol.
- compositions can be used for the prophylaxis and / or treatment of diseases of humans or animals in the form of the following formulations ("Substance" means the active ingredient):
- composition for injection I 50 mg / ml
- Tablets (l) - (ll) can be enteric coated using, for example, cellulose acetate phthalate.
- Polymorphic modification “B” of the monohydrate of the salt of 4-methylbenzenesulfonic acid and the base 2,2-dimethyl-6 - ((4 - ((3,4,5-trimethoxyphenyl) amino) -1, 3,5-triazin-2- il) amino) -2H-pyrido [3,2-b] [1, 4] oxazin-3 (4H) -one can also be obtained by treating polymorphic modification "A” with ethanol or another solvent.
- salt forms of Compound 1 were synthesized.
- the main goal of optimizing the salt form was to obtain a salt form of Compound 1 with the following characteristics: crystallinity, consistency of composition, therapeutic efficacy, safety of use in therapy, ease of scaling of the preparation process , the use of a pharmacologically acceptable counterion (preferably anion), the use of low toxic organic dissolve lei.
- the preparation of salt forms of Compound 1 was carried out in organic solvents with high polarity and low toxicity (Class 3). Counterions were used on the basis of pharmacological acceptability and high acid strength (pKa not higher than 3.25). The requirement for a high acid strength is due to the fact that the protonated pyridine nitrogen atom of Compound 1 is a weak base with pKa 4.
- test samples S-3-1-B-TSA (hereinafter S3-1), S-3-2-B-HBr (S3-2), S-3-4 -B-HCI (S3-4), S-3-8-B-HBr (S3-8), S-3-9-B-CSA (S3-9), S-3-10-B-HCI ( S3-10), S-3-1 1 -C2-HCI (S3-1 1), S-3-12-A1-TSA (S3-12), S-3-16-D-SA (S3-16 ) M S-3-17-D-MSA (S3-17)) had crystalline phases.
- Sample S-3-10-B-HCI is an individual crystalline phase, however, due to the large line width and low reflectivity of the sample, the indication is ambiguous.
- Space group Pi
- Sample S-3-1 1 -C2-HCI also represents a crystalline phase and is also ambiguously indicated.
- the non-crystalline phase peak observed in the region of 22.7 ° 2 ⁇ refers to the Kapton substrate (see Figure 9a).
- the positions and intensities of the characteristic, visually distinguishable peaks in the de-gram of sample S-3-12-A1-TSA are presented in Table 2.
- Table 2 General view of the independent part of the unit cell of the 4-methylbenzenesulfonic acid salt hydrate and Compound 1 in polymorphic modification “A” (sample S-3 -12-A1-TSA) is shown in Figure 1 1a.
- Table 2 Positions and intensities of characteristic, visually distinguishable peaks on the de-gram of a sample of 4-methylbenzenesulfonic acid salt hydrate and base of Compound 1 (Polymorphic modification “A”). Intensities are heights (adjusted for background) of peaks. The provisions correspond to the maximums on the de-gram, and not to the calculated positions of the reflections.
- sample S-3-10-B-HCI S-3-10
- S-3-1 1 -C2-HCI S3-1 1
- S-3-12-A1-TSA S3-12
- sample S3-12-A1-TSA is a monohydrate.
- DSC differential scanning calorimetry
- TGA thermogravimetry of the sample
- the measuring system was calibrated according to ISO 11357-1 according to the phase transition parameters of standard substances (C 6 H 12 ; Nd; benzoic acid; Ga; KN0 3 ; In; Sn; Bi; CsCI; 99.99% purity).
- the systematic error of the temperature calibration is 0.1 °.
- TGA measurements were performed on a NETZSCH TG 209 F1 thermobalance equipped with an alundum holder with a protective shield and a type P temperature sensor.
- the device was calibrated by the melting points of standard substances (Ag; AI; Bi; In; Sn; 99.99% purity).
- the error in determining the mass does not exceed 0.1% (determined according to the standard CaC 2 0 4 -2H 2 0).
- the experimental data were processed using the NETZSCH Proteus Analysis analysis package according to ISO / CD 1 1358.
- the sample was weighed on an AND GH 202 analytical balance with an accuracy of ⁇ 0.01 mg.
- the material was not machined prior to measurement to avoid dehydration.
- Table 3 Positions and intensities of characteristic, visually distinguishable peaks on the de-gram of a sample of 4-methylbenzenesulfonic acid salt hydrate and base of Compound 1 (Polymorphic modification “B”). Intensities are the heights (corrected for background) of the peaks.
- the provisions correspond to the maximums on the de-gram, and not to the calculated positions of the reflections.
- Table 4 The results of the analysis of the content of impurities in the sample of Compound 1 (in the form of a free base).
- Compound 1 in the form of a free base showed a high content of various unidentified impurities in the samples, the presence of which can lead to toxic effects, and can also cause side effects due to the introduction of this compound into the human and animal body as a medicine. Therefore, to use Compound 1 as a drug candidate, additional purification steps are required. The use of additional stages of purification will inevitably lead to a complication of the technological scheme and an increase in the cost of production of the final drug.
- the residual activity of c-Src kinase in the presence of a salt of 4-methylbenzenesulfonic acid and Compound 1 at a concentration of 0.5 ⁇ mol / L was 6% of the control values, Yes and Lck kinases - 12%, Lyn kinases - 13%, Blk - 20%, Fgr - 23%, Fyn and Hck - 25%.
- the concentrations of half-maximal inhibition (IC 50 ) of the enzymatic activity of the kinase were determined.
- the inhibitory effect of the 4-methylbenzenesulfonic acid salt and Compound 1 on the recombinant human tyrosine kinase c-Src was shown.
- the pharmacokinetics of the free base of Compound 1 was studied after oral administration of the substance to three Wistar rats at a dose of 30 mg / kg.
- the results of the study are shown in Figure 19 and Table 9.
- the maximum concentration of the substance in the plasma is 4, 12 ng / ml, which corresponds to 9, 1 nmol / L, and the average daily concentration of the substance is 4.8 nmol / L .
- the effective concentration of the free base is about 1 ⁇ mol / L.
- the pharmacokinetic parameters of the free base exclude the possibility of its use as a medicine, since in order to achieve the necessary therapeutic effect it is necessary to introduce a large the dose of Compound 1, which is extremely inconvenient technically for practical implementation, leads to a significant consumption of the substance, and can also potentially lead to the development of toxic side effects from the gastrointestinal tract.
- Table 9 Basic pharmacokinetic parameters of Compound 1 when administered as a free base to Wistar rats at a dose of 30 mg / kg. For each time point, average values are determined based on individual data from three animals.
- FIG. 1 after oral administration of the substance to Wistar rats at a dose of 37 mg / kg (30 mg / kg in terms of free base).
- Figure 20 and table 10 show the results of a study of the pharmacokinetic parameters of the methanesulfonic acid salt and Compound 1.
- the maximum concentration of a substance in plasma is 333 ng / ml, which corresponds to 735 nmol / L, and the average concentration of a substance is 104 nmol / L.
- the effective concentration of Compound 1 is of the order of 1 ⁇ mol / L.
- Table 10 Basic pharmacokinetic parameters of methanesulfonic acid salt and Compound 1 when administered to Wistar rats at a dose of 30 mg / kg (calculated on the free base). For each time point, average values are determined based on individual data from three animals.
- the maximum concentration of the substance in plasma is 416 ng / ml, which corresponds to approximately 1 ⁇ mol / L, and the average daily concentration of the substance exceeds 200 nmol / L.
- Table 11 The main pharmacokinetic parameters of the 4-methylbenzenesulfonic acid salt hydrate and Compound 1 (polymorphic modification "A") when Wistar rats were administered at a dose of 21 mg / kg (calculated on the free base). For each time point, average values are determined based on individual data from six animals.
- the 4-methylbenzenesulfonic acid and Compound 1 salt hydrate has linear pharmacokinetics in a wide dose range - with intragastric administration of the 4-methylbenzenesulfonic acid and Compound 1 salt hydrate in a dose range of 30 to 200 mg / kg, the concentration of Compound 1 in rat blood plasma increases in proportion to the dose.
- the proliferation medium was removed and the cells were differentiated in a differentiation medium (aMEM / FCS-10% with 100 ng / ml RANKL and 25 ng / ml M-CSF).
- aMEM / FCS-10% with 100 ng / ml RANKL and 25 ng / ml M-CSF.
- the cells were harvested and subcultured in a 96-well plate coated with a synthetic mineralized matrix and cultured for another 48 hours (in the presence of the studied compounds) to evaluate osteoclast resorption. Then an estimate was made of the number of mature osteoclasts and an assessment of the degree of resorption.
- Isolated chondrocytes in a culture medium minimum maintenance medium A needle modified by the Dulbecco / fetal calf serum method (DMEM / FCS) - 10%, 4- (2-hydroxyethyl) -1-piperazine ethanesulfonic acid (HEPES) - 25 mM) were stored frozen at -80 ° C. The obtained chondrocytes were thawed a day before the start of the experiment, planted in 12 well plates and cultured as a monolayer for 24 hours. 11 _- ⁇ - the induced activation of chondrocytes and treatment with the test compounds was started after 24 hours of incubation and continued for 3 days.
- DMEM / FCS Dulbecco / fetal calf serum method
- HEPES 4- (2-hydroxyethyl) -1-piperazine ethanesulfonic acid
- the salt of 4-methylbenzenesulfonic acid and Compound 1 as well as its hydrate (in particular, monohydrate), solvate and polymorphic modifications of the salt, hydrate or solvate are effective inhibitors of Syk kinase and Src kinases, in particular c-Src kinases, and have pharmacokinetic parameters that allow the use of these salts as a drug for administration to a human or animal organism for the treatment of diseases associated with aberrant activity kinases leading to aberrant metabolism of bone and cartilage, in particular, osteoarthritis, osteoporosis and osteochondrosis.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL17796477T PL3456720T3 (pl) | 2016-05-13 | 2017-05-10 | Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych |
ES17796477T ES2892274T3 (es) | 2016-05-13 | 2017-05-10 | Novedosa forma de sal cristalina de 2,2-dimetil-6-((4-((3,4,5-trimetoxifenil)amino)-1,3,5-triazin-2-il)amino)-2H-pirido[3,2-b][1,4]oxazin-3(4H)-ona para aplicación médica |
AU2017264302A AU2017264302B2 (en) | 2016-05-13 | 2017-05-10 | Novel crystalline salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2H-pyrido[3,2-B][1,4]oxazin-3(4H)-one for medical application |
JP2019512598A JP6980299B2 (ja) | 2016-05-13 | 2017-05-10 | 医療用途のための2,2−ジメチル−6−((4−((3,4,5−トリメトキシフェニル)アミノ)−1,3,5−トリアジン−2−イル)アミノ)−2hピリド[3,2−b][1,4]オキサジン−3(4h)−オンの新規結晶塩形 |
EA201892589A EA037460B1 (ru) | 2016-05-13 | 2017-05-10 | НОВАЯ КРИСТАЛЛИЧЕСКАЯ СОЛЕВАЯ ФОРМА 2,2-ДИМЕТИЛ-6-((4-((3,4,5-ТРИМЕТОКСИФЕНИЛ)АМИНО)-1,3,5-ТРИАЗИН-2-ИЛ)АМИНО)-2H-ПИРИДО[3,2-b][1,4]ОКСАЗИН-3(4H)-ОНА ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ |
DK17796477.2T DK3456720T3 (da) | 2016-05-13 | 2017-05-10 | Hidtil ukendt krystallinsk saltform af 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-on til medicinsk anvendelse |
EP17796477.2A EP3456720B1 (en) | 2016-05-13 | 2017-05-10 | Novel crystalline salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one for medical application |
CN201780043307.1A CN109526221B (zh) | 2016-05-13 | 2017-05-10 | 一种激酶抑制剂的晶体盐形式 |
US16/301,148 US10745414B2 (en) | 2016-05-13 | 2017-05-10 | Crystal salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazine-2-yl)amino)-2H-pyrido[3,2-b][1,4]oxazine-3(4H)-one for human use |
CA3023231A CA3023231A1 (en) | 2016-05-13 | 2017-05-10 | A new crystal salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazine-3(4h)-one for human use |
KR1020187036184A KR102522102B1 (ko) | 2016-05-13 | 2017-05-10 | 의학적 적용을 위한 2,2-디메틸-6-((4-((3,4,5-트리메톡시페닐)아미노)-1,3,5-트리아진-2-일)아미노)-2h-피리도[3,2-b][1,4]옥사진-3(4h)-온의 신규한 결정질 염 형태 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015147258 | 2016-05-13 | ||
RU2015147258A RU2621187C1 (ru) | 2016-05-13 | 2016-05-13 | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017196210A1 true WO2017196210A1 (ru) | 2017-11-16 |
Family
ID=59032468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2017/050037 WO2017196210A1 (ru) | 2016-05-13 | 2017-05-10 | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2h-пиридо[3,2-b][1,4]оксазин-3(4h)-она для медицинского применения |
Country Status (13)
Country | Link |
---|---|
US (1) | US10745414B2 (ru) |
EP (1) | EP3456720B1 (ru) |
JP (1) | JP6980299B2 (ru) |
KR (1) | KR102522102B1 (ru) |
CN (1) | CN109526221B (ru) |
AU (1) | AU2017264302B2 (ru) |
CA (1) | CA3023231A1 (ru) |
DK (1) | DK3456720T3 (ru) |
EA (1) | EA037460B1 (ru) |
ES (1) | ES2892274T3 (ru) |
PL (1) | PL3456720T3 (ru) |
RU (1) | RU2621187C1 (ru) |
WO (1) | WO2017196210A1 (ru) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007124221A1 (en) * | 2006-04-18 | 2007-11-01 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
RU2509770C2 (ru) * | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
CN102358738A (zh) * | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
WO2015047124A1 (ru) * | 2013-09-26 | 2015-04-02 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
-
2016
- 2016-05-13 RU RU2015147258A patent/RU2621187C1/ru active
-
2017
- 2017-05-10 DK DK17796477.2T patent/DK3456720T3/da active
- 2017-05-10 JP JP2019512598A patent/JP6980299B2/ja active Active
- 2017-05-10 WO PCT/RU2017/050037 patent/WO2017196210A1/ru unknown
- 2017-05-10 AU AU2017264302A patent/AU2017264302B2/en active Active
- 2017-05-10 US US16/301,148 patent/US10745414B2/en active Active
- 2017-05-10 CN CN201780043307.1A patent/CN109526221B/zh active Active
- 2017-05-10 CA CA3023231A patent/CA3023231A1/en active Pending
- 2017-05-10 EP EP17796477.2A patent/EP3456720B1/en active Active
- 2017-05-10 ES ES17796477T patent/ES2892274T3/es active Active
- 2017-05-10 KR KR1020187036184A patent/KR102522102B1/ko active IP Right Grant
- 2017-05-10 EA EA201892589A patent/EA037460B1/ru unknown
- 2017-05-10 PL PL17796477T patent/PL3456720T3/pl unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007124221A1 (en) * | 2006-04-18 | 2007-11-01 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
RU2509770C2 (ru) * | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
Non-Patent Citations (2)
Title |
---|
RAKITINA TATIANA V. ET AL.: "Efficacy of novel Syk-kinase inhibitors MT-SYK-03 and MT-SYK-322 in cellular models of autoimmunity and cancer", MENDELEEV COMMUNICATIONS, vol. 22, no. 6, 2012, pages 287 - 289, XP055439315 * |
See also references of EP3456720A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017264302A1 (en) | 2019-01-03 |
EP3456720A1 (en) | 2019-03-20 |
JP6980299B2 (ja) | 2021-12-15 |
CA3023231A1 (en) | 2017-11-16 |
EA201892589A1 (ru) | 2019-04-30 |
PL3456720T3 (pl) | 2021-12-06 |
JP2019515053A (ja) | 2019-06-06 |
ES2892274T3 (es) | 2022-02-03 |
KR102522102B1 (ko) | 2023-04-13 |
AU2017264302B2 (en) | 2021-05-27 |
US20190292198A1 (en) | 2019-09-26 |
EA037460B1 (ru) | 2021-03-30 |
DK3456720T3 (da) | 2021-09-27 |
CN109526221A (zh) | 2019-03-26 |
EP3456720B1 (en) | 2021-06-30 |
CN109526221B (zh) | 2022-06-21 |
KR20190005996A (ko) | 2019-01-16 |
US10745414B2 (en) | 2020-08-18 |
EP3456720A4 (en) | 2019-10-30 |
RU2621187C1 (ru) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11667627B2 (en) | Salt and crystal forms of PLK-4 inhibitor | |
AU2016377782B2 (en) | CFTR regulators and methods of use thereof | |
AU2012324405B2 (en) | New salt and medical use | |
AU2016379444B2 (en) | CFTR regulators and methods of use thereof | |
WO1990015600A2 (en) | Treatment of chronic inflammatory joint disease with arylsulfonamides | |
RU2621187C1 (ru) | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения | |
KR20120099215A (ko) | 다운 증후군을 치료하기 위한 방법 및 약학적 조성물 | |
JP2020525415A (ja) | 医薬組成物及びその製造方法 | |
US11945814B2 (en) | Salt form | |
US7338970B2 (en) | Pharmaceutical composition based on a polymorphic form I of idazoxan | |
EP4324827A1 (en) | Pharmaceutically acceptable salt of sphingosine-1-phosphate receptor agonist, and crystalline form thereof | |
EP3170819A1 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
WO2023087034A1 (en) | Salts and solid forms of 4-bromo-2,5-dimethoxyphenethylamine | |
BR112019019649A2 (pt) | forma hidratada e cristalina de dimaleato de afatinibe, composição farmacêutica, e, métodos para tratamento de doença em um paciente e para produção da forma z. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3023231 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019512598 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17796477 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20187036184 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017264302 Country of ref document: AU Date of ref document: 20170510 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017796477 Country of ref document: EP Effective date: 20181213 |